Breaking Bottlenecks for the TCR Therapy of Cancer
Open accessAbstract
Immune checkpoint inhibitors have redefined the treatment of cancer, but their efficacy depends critically on the presence of sufficient tumor-specific lymphocytes, and cellular immunotherapies develop rapidly to fill this gap. The paucity of suitable extracellular and tumor-associated antigens in solid cancers necessitates the use of neoantigen-directed T-cell-receptor (TCR)-engineered cells, while prevention of tumor evasion requires combined targeting of multiple neoepitopes. These can be currently identified within 2 weeks by combining cutting-edge next-generation sequencing with bioinformatic pipelines and used to select tumor-reactive TCRs in a high-throughput manner for expeditious scalable non-viral gene editing of autologous or allogeneic lymphocytes. “Young” cells with a naive, memory stem or central memory phenotype can be additionally armored with “next-generation” features against exhaustion and the immunosuppressive tumor microenvironment, where they wander after reinfusion to attack heavily pretreated and hitherto hopeless neoplasms. Facilitated by major technological breakthroughs in critical manufacturing steps, based on a solid preclinical rationale, and backed by rapidly accumulating evidence, TCR therapies break one bottleneck after the other and hold the promise to become the next immuno-oncological revolution.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Adoptive cell therapy (ACT) has demonstrated promising results in cases with high numbers of quality tumor-specific lymphocytes.
“Interestingly, adoptive cell therapy (ACT) has demonstrated promising results in cases with these characteristics [17].”
From Current and Future Trends of Colorectal Cancer Treatment: Exploring Advances in Immunotherapy (2024) · cites this paper as [17]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Tissue-based map of the human proteome
Uhlén, M., Fagerberg, L., Hallström, B. M., Lindskog, C., Oksvold, P., Mardinoglu, A., Sivertsson, Å., Kampf, C., Sjöstedt, E., Asplund, A., et al. (2015) · Science · doi:10.1126/science.1260419 · Cited by 15,286 · see citing works
Pushko, P., Pumpens, P., & Grens, E. (2013) · Intervirology · doi:10.1159/000346773 · Cited by 5,970 · see citing works
Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia
Maude, S. L., Frey, N., Shaw, P. A., Aplenc, R., Barrett, D. M., Bunin, N. J., Chew, A., Gonzalez, V. E., Zheng, Z., Lacey, S. F., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1407222 · Cited by 5,413 · cited 1× · see citing works
“Clinical trials of CD19-directed CAR-T cells have indeed shown treatment failures to be mostly CD19-negative [44,45], and the same limitation also pertains to TCR-based ACT, necessitating the use of multivalent products [46].”
BackgroundOverall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
Wolchok, J. D., Chiarion-Sileni, V., Gonzalez, R., Rutkowski, P., Grob, J.-J., Cowey, C. L., Lao, C. D., Wagstaff, J., Schadendorf, D., Ferrucci, P. F., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1709684 · Cited by 5,357 · see citing works
Neoantigens in cancer immunotherapy
Schumacher, T. N., & Schreiber, R. D. (2015) · Science · doi:10.1126/science.aaa4971 · Cited by 4,783 · see citing works
Massagué, J. (2008) · Cell · doi:10.1016/j.cell.2008.07.001 · Cited by 3,907 · see citing works
Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
Larkin, J., Chiarion-Sileni, V., Gonzalez, R., Grob, J.-J., Rutkowski, P., Lao, C. D., Cowey, C. L., Schadendorf, D., Wagstaff, J., Dummer, R., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1910836 · Cited by 3,723 · see citing works
Fundamental Mechanisms of Immune Checkpoint Blockade Therapy
Wei, S. C., Duffy, C. R., & Allison, J. P. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-0367 · Cited by 3,088 · see citing works
An immunogenic personal neoantigen vaccine for patients with melanoma
Ott, P. A., Hu, Z., Keskin, D. B., Shukla, S. A., Sun, J., Bozym, D. J., Zhang, W., Luoma, A., Giobbie-Hurder, A., Peter, L., et al. (2017) · Nature · doi:10.1038/nature22991 · Cited by 2,936 · see citing works
Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer
Sahin, U., Derhovanessian, E., Miller, M., Kloke, B.-P., Simon, P., Löwer, M., Bukur, V., Tadmor, A. D., Luxemburger, U., Schrörs, B., et al. (2017) · Nature · doi:10.1038/nature23003 · Cited by 2,488 · see citing works
Rosenberg, S. A., Yang, J. C., Sherry, R. M., Kammula, U. S., Hughes, M. S., Phan, G. Q., Citrin, D. E., Restifo, N. P., Robbins, P. F., Wunderlich, J. R., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-0116 · Cited by 2,145 · see citing works
Couzin-Frankel, J. (2013) · Science · doi:10.1126/science.342.6165.1432 · Cited by 2,051 · see citing works
Targeting a CAR to the TRAC locus with CRISPR/Cas9 enhances tumour rejection
Eyquem, J., Mansilla-Soto, J., Giavridis, T., van der Stegen, S. J. C., Hamieh, M., Cunanan, K. M., Odak, A., Gönen, M., & Sadelain, M. (2017) · Nature · doi:10.1038/nature21405 · Cited by 1,831 · see citing works
Cancer Immunotherapy Based on Mutation-Specific CD4+ T Cells in a Patient with Epithelial Cancer
Tran, E., Turcotte, S., Gros, A., Robbins, P. F., Lu, Y., Dudley, M. E., Wunderlich, J. R., Somerville, R. P. T., Hogan, K., Hinrichs, C. S., et al. (2014) · Science · doi:10.1126/science.1251102 · Cited by 1,710 · see citing works
Inducible Apoptosis as a Safety Switch for Adoptive Cell Therapy
Di Stasi, A., Tey, S.-K., Dotti, G., Fujita, Y., Kennedy-Nasser, A., Martinez, C., Straathof, K., Liu, E., Durett, A. G., Grilley, B., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1106152 · Cited by 1,512 · see citing works
CRISPR-engineered T cells in patients with refractory cancer
Stadtmauer, E. A., Fraietta, J. A., Davis, M. M., Cohen, A. D., Weber, K. L., Lancaster, E., Mangan, P. A., Kulikovskaya, I., Gupta, M., Chen, F., et al. (2020) · Science · doi:10.1126/science.aba7365 · Cited by 1,478 · see citing works
Spranger, S., Dai, D., Horton, B., & Gajewski, T. F. (2017) · Cancer Cell · doi:10.1016/j.ccell.2017.04.003 · Cited by 1,441 · see citing works
Johnson, L. A., Morgan, R. A., Dudley, M. E., Cassard, L., Yang, J. C.-H., Hughes, M. S., Kammula, U. S., Royal, R. E., Sherry, R. M., Wunderlich, J. R., et al. (2009) · Blood · doi:10.1182/blood-2009-03-211714 · Cited by 1,421 · see citing works
A Paradigm Shift in Cancer Immunotherapy: From Enhancement to Normalization
Sanmamed, M. F., & Chen, L. (2018) · Cell · doi:10.1016/j.cell.2018.09.035 · Cited by 1,394 · see citing works
Epigenetic stability of exhausted T cells limits durability of reinvigoration by PD-1 blockade
Pauken, K. E., Sammons, M. A., Odorizzi, P. M., Manne, S., Godec, J., Khan, O., Drake, A. M., Chen, Z., Sen, D. R., Kurachi, M., et al. (2016) · Science · doi:10.1126/science.aaf2807 · Cited by 1,348 · cited 1× · see citing works
“However, a major limitation of current approaches to counter T-cell exhaustion is the epigenetic stability of Tex, which limits durability of reinvigoration [131].”
Background‘Off-the-shelf’ allogeneic CAR T cells: development and challenges
Depil, S., Duchateau, P. N., Grupp, S. A., Mufti, G. J., & Poirot, L. (2020) · Nature Reviews Drug Discovery · doi:10.1038/s41573-019-0051-2 · Cited by 1,238 · see citing works
Garon, E. B., Hellmann, M. D., Rizvi, N. A., Carcereny, E., Leighl, N. B., Ahn, M.-J., Eder, J. P., Balmanoukian, A. S., Aggarwal, C., Horn, L., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.19.00934 · Cited by 1,231 · see citing works
Tumor Antigen Escape from CAR T-cell Therapy
Majzner, R. G., & Mackall, C. L. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-0442 · Cited by 1,201 · see citing works
Vaddepally, R. K., Kharel, P., Pandey, R. K., Garje, R., & Chandra, A. B. (2020) · Cancers · doi:10.3390/cancers12030738 · Cited by 1,189 · see citing works
Linette, G. P., Stadtmauer, E. A., Maus, M. V., Rapoport, A. P., Levine, B. L., Emery, L., Litzky, L. A., Bagg, A., Carreno, B. M., Cimino, P. J., et al. (2013) · Blood · doi:10.1182/blood-2013-03-490565 · Cited by 1,183 · see citing works
Cancer Regression and Neurological Toxicity Following Anti-MAGE-A3 TCR Gene Therapy
Morgan, R. A., Chinnasamy, N., Abate‐Daga, D., Gros, A., Robbins, P. F., Zheng, Z., Dudley, M. E., Feldman, S. A., Yang, J. C., Sherry, R. M., et al. (2013) · Journal of Immunotherapy · doi:10.1097/cji.0b013e3182829903 · Cited by 1,155 · see citing works
Serial triggering of many T-cell receptors by a few peptide–MHC complexes
Valitutti, S., Müller, S., Cella, M., Padovan, E., & Lanzavecchia, A. (1995) · Nature · doi:10.1038/375148a0 · Cited by 1,133 · see citing works
PD-1 identifies the patient-specific CD8+ tumor-reactive repertoire infiltrating human tumors
Gros, A., Robbins, P. F., Yao, X., Li, Y. F., Turcotte, S., Tran, E., Wunderlich, J. R., Mixon, A., Farid, S., Dudley, M. E., et al. (2014) · Journal of Clinical Investigation · doi:10.1172/jci73639 · Cited by 1,113 · see citing works
Cold Tumors: A Therapeutic Challenge for Immunotherapy
Bonaventura, P., Shekarian, T., Alcazer, V., Valladeau‐Guilemond, J., Valsesia‐Wittmann, S., Amigorena, S., Caux, C., & Depil, S. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00168 · Cited by 1,102 · see citing works
Parkhurst, M. R., Yang, J. C.-H., Langan, R. C., Dudley, M. E., Nathan, D.-A. N., Feldman, S. A., Davis, J. L., Morgan, R. A., Merino, M. J., Sherry, R. M., et al. (2010) · Molecular Therapy · doi:10.1038/mt.2010.272 · Cited by 1,025 · see citing works
Precision Tumor Recognition by T Cells With Combinatorial Antigen-Sensing Circuits
Roybal, K. T., Rupp, L. J., Morsut, L., Walker, W. J., McNally, K. A., Park, J. S., & Lim, W. A. (2016) · Cell · doi:10.1016/j.cell.2016.01.011 · Cited by 1,010 · see citing works
Targeting neoantigens to augment antitumour immunity
Yarchoan, M., Johnson, B. A., Lutz, E. R., Laheru, D. A., & Jaffee, E. M. (2017) · Nature Reviews Cancer · doi:10.1038/nrc.2016.154 · Cited by 997 · see citing works
Co-expression of CD39 and CD103 identifies tumor-reactive CD8 T cells in human solid tumors
Duhen, T., Duhen, R., Montler, R., Moses, J., Moudgil, T., de Miranda, N. F., Goodall, C. P., Blair, T. C., Fox, B. A., McDermott, J. E., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-05072-0 · Cited by 938 · see citing works
c-Jun overexpression in CAR T cells induces exhaustion resistance
Lynn, R. C., Weber, E. W., Sotillo, E., Gennert, D., Xu, P., Good, Z., Anbunathan, H., Lattin, J., Jones, R., Tieu, V., et al. (2019) · Nature · doi:10.1038/s41586-019-1805-z · Cited by 891 · cited 3× · see citing works
“Genetic engineering to overexpress c-Jun, a protein that combines with c-Fos to form the transcription factor AP-1, can also increase expansion and prolong survival of adoptively transferred T cells after reinfusion by driving transcription of IL-2 [114].”
BackgroundInfluentialTherapeutic T cell engineering
Sadelain, M., Rivière, I., & Riddell, S. R. (2017) · Nature · doi:10.1038/nature22395 · Cited by 886 · see citing works
Rapoport, A. P., Stadtmauer, E. A., Binder-Scholl, G. K., Goloubeva, O. G., Vogl, D. T., Lacey, S. F., Badros, A. Z., Garfall, A. L., Weiss, B. M., Finklestein, J. M., et al. (2015) · Nature Medicine · doi:10.1038/nm.3910 · Cited by 857 · see citing works
Imai, C., Mihara, K., Andreánsky, M., Nicholson, I., Pui, C., Geiger, T. L., & Campana, D. (2004) · Leukemia · doi:10.1038/sj.leu.2403302 · Cited by 844 · see citing works
Reprogramming human T cell function and specificity with non-viral genome targeting
Roth, T. L., Puig-Saus, C., Yu, R., Shifrut, E., Carnevale, J., Li, P. J., Hiatt, J., Saco, J., Krystofinski, P., Li, H., et al. (2018) · Nature · doi:10.1038/s41586-018-0326-5 · Cited by 839 · see citing works
Berger, C., Jensen, M. C., Lansdorp, P. M., Gough, M., Elliott, C., & Riddell, S. R. (2008) · Journal of Clinical Investigation · doi:10.1172/jci32103 · Cited by 822 · see citing works
Revisiting the role of CD4+ T cells in cancer immunotherapy—new insights into old paradigms
Tay, R. E., Richardson, E. K., & Toh, H. C. (2020) · Cancer Gene Therapy · doi:10.1038/s41417-020-0183-x · Cited by 801 · see citing works
Adachi, K., Kano, Y., Nagai, T., Okuyama, N., Sakoda, Y., & Tamada, K. (2018) · Nature Biotechnology · doi:10.1038/nbt.4086 · Cited by 796 · see citing works
T cell anergy, exhaustion, senescence, and stemness in the tumor microenvironment
Crespo, J., Sun, H., Welling, T. H., Tian, Z., & Zou, W. (2013) · Current Opinion in Immunology · doi:10.1016/j.coi.2012.12.003 · Cited by 752 · see citing works
TRUCKs: the fourth generation of CARs
Chmielewski, M. M., & Abken, H. (2015) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2015.1046430 · Cited by 750 · see citing works
Gettinger, S. N., Horn, L., Jackman, D. M., Spigel, D. R., Antonia, S. J., Hellmann, M. D., Powderly, J. D., Heist, R. S., Sequist, L. V. D., Smith, D. C., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.77.0412 · Cited by 740 · see citing works
Fedorov, V. D., Themeli, M., & Sadelain, M. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3006597 · Cited by 737 · see citing works
Evidence that a Single Peptide–MHC Complex on a Target Cell Can Elicit a Cytolytic T Cell Response
Sykulev, Y. K., Joo, M., Vturina, I., Tsomides, T. J., & Eisen, H. N. (1996) · Immunity · doi:10.1016/s1074-7613(00)80483-5 · Cited by 708 · see citing works
Tandem CAR T cells targeting HER2 and IL13Rα2 mitigate tumor antigen escape
Hegde, M. G., Mukherjee, M., Grada, Z., Pignata, A., Landi, D. B., Navai, S. A., Wakefield, A., Fousek, K., Bielamowicz, K., Chow, K. K. H., et al. (2016) · Journal of Clinical Investigation · doi:10.1172/jci83416 · Cited by 681 · see citing works
Shrimali, R. K., Yu, Z., Theoret, M. R., Chinnasamy, D., Restifo, N. P., & Rosenberg, S. A. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-0153 · Cited by 677 · see citing works
Schumacher, T. N., Scheper, W., & Kvistborg, P. (2018) · Annual Review of Immunology · doi:10.1146/annurev-immunol-042617-053402 · Cited by 578 · see citing works
Low and variable tumor reactivity of the intratumoral TCR repertoire in human cancers
Scheper, W., Kelderman, S., Fanchi, L. F., Linnemann, C., Bendle, G. M., de Rooij, M. A. J., Hirt, C., Mezzadra, R., Slagter, M., Dijkstra, K. K., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0266-5 · Cited by 568 · see citing works
Moon, E. K., Carpenito, C., Sun, J., Wang, L. S., Kapoor, V., Predina, J. D., Powell, D. J., Riley, J. L., June, C. H., & Albelda, S. Μ. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-0351 · Cited by 537 · see citing works
Craddock, J. A., Lu, A., Bear, A. S., Pulè, M. A., Brenner, M. K., Rooney, C. M., & Foster, A. E. (2010) · Journal of Immunotherapy · doi:10.1097/cji.0b013e3181ee6675 · Cited by 514 · see citing works
Recent Advances in Targeting CD8 T-Cell Immunity for More Effective Cancer Immunotherapy
Durgeau, A., Virk, Y., Corgnac, S., & Mami‐Chouaib, F. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.00014 · Cited by 495 · see citing works
Ciceri, F., Bonini, C., Stanghellini, M. T. L., Bondanza, A., Traversari, C., Salomoni, M., Turchetto, L., Colombi, S., Bernardi, M., Peccatori, J., et al. (2009) · The Lancet Oncology · doi:10.1016/s1470-2045(09)70074-9 · Cited by 485 · see citing works
Cohen, C. J., Zhao, Y., Zheng, Z., Rosenberg, S. A., & Morgan, R. A. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-1450 · Cited by 465 · see citing works
Wölfl, M., Kuball, J. H. E., Ho, W., Nguyen, H., Manley, T. J., Bleakley, M., & Greenberg, P. D. (2007) · Blood · doi:10.1182/blood-2006-11-056168 · Cited by 460 · see citing works
Editing T cell specificity towards leukemia by zinc finger nucleases and lentiviral gene transfer
Provasi, E., Genovese, P., Lombardo, A., Magnani, Z., Liu, P.-Q., Reik, A., Chu, V., Paschon, D. E., Zhang, L., Kuball, J., et al. (2012) · Nature Medicine · doi:10.1038/nm.2700 · Cited by 448 · see citing works
Targeting of cancer neoantigens with donor-derived T cell receptor repertoires
Strønen, E., Toebes, M., Kelderman, S., van Buuren, M. M., Yang, W., van Rooij, N., Donia, M., Böschen, M.-L., Lund‐Johansen, F., Olweus, J., et al. (2016) · Science · doi:10.1126/science.aaf2288 · Cited by 444 · see citing works
'Final common pathway' of human cancer immunotherapy: targeting random somatic mutations
Tran, E., Robbins, P. F., & Rosenberg, S. A. (2017) · Nature Immunology · doi:10.1038/ni.3682 · Cited by 443 · see citing works
Directed evolution of human T-cell receptors with picomolar affinities by phage display
Li, Y., Moysey, R. K., Molloy, P. E., Vuidepot, A., Mahon, T., Baston, E., Dunn, S. M., Liddy, N., Jacob, J. P., Jakobsen, B. K., et al. (2005) · Nature Biotechnology · doi:10.1038/nbt1070 · Cited by 442 · see citing works
D’Angelo, S. P., Melchiori, L., Merchant, M. S., Bernstein, D. B., Glod, J. W., Kaplan, R. N., Grupp, S. A., Tap, W. D., Chagin, K., Binder, G. K., et al. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-1417 · Cited by 432 · see citing works
Engineered T Cell Therapy for Cancer in the Clinic
Zhao, L., & Cao, Y. J. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.02250 · Cited by 414 · see citing works
Hinrichs, C., Borman, Z. A., Cassard, L., Gattinoni, L., Spolski, R., Yu, Z.-Y., Sanchez-Perez, L., Muranski, P., Kern, S., Logun, C., et al. (2009) · Proceedings of the National Academy of Sciences of the United States of America · doi:10.1073/pnas.0907448106 · Cited by 407 · see citing works
Trafficking of T Cells into Tumors
Slaney, C. Y., Kershaw, M. H., & Darcy, P. K. (2014) · Cancer Research · doi:10.1158/0008-5472.can-14-2458 · Cited by 406 · see citing works
Single and Dual Amino Acid Substitutions in TCR CDRs Can Enhance Antigen-Specific T Cell Functions
Robbins, P. F., Li, Y. F., El‐Gamil, M., Zhao, Y., Wargo, J. A., Zheng, Z., Xu, H., Morgan, R. A., Feldman, S. A., Johnson, L. A., et al. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.180.9.6116 · Cited by 385 · see citing works
Krause, A., Guo, H.-F., Latouche, J., Tan, C., Cheung, N. V., & Sadelain, M. (1998) · The Journal of Experimental Medicine · doi:10.1084/jem.188.4.619 · Cited by 368 · see citing works
Prospects for gene-engineered T cell immunotherapy for solid cancers
Klebanoff, C. A., Rosenberg, S. A., & Restifo, N. P. (2016) · Nature Medicine · doi:10.1038/nm.4015 · Cited by 366 · see citing works
Gotter, J., Brors, B., Hergenhahn, M., & Kyewski, B. (2004) · The Journal of Experimental Medicine · doi:10.1084/jem.20031677 · Cited by 363 · see citing works
Mass spectrometry–based identification of MHC-bound peptides for immunopeptidomics
Purcell, A. W., Ramarathinam, S. H., & Ternette, N. (2019) · Nature Protocols · doi:10.1038/s41596-019-0133-y · Cited by 362 · see citing works
Quantitative Analysis of the Contribution of TCR/pepMHC Affinity and CD8 to T Cell Activation
Holler, P. D., & Kranz, D. M. (2003) · Immunity · doi:10.1016/s1074-7613(03)00019-0 · Cited by 348 · see citing works
Biopolymers codelivering engineered T cells and STING agonists can eliminate heterogeneous tumors
Smith, T. T., Moffett, H. F., Stephan, S. B., Opel, C. F., Dumigan, A., Jiang, X., Pillarisetty, V. G., Pillai, S. P. S., Wittrup, K. D., & Stephan, M. T. (2017) · Journal of Clinical Investigation · doi:10.1172/jci87624 · Cited by 339 · see citing works
T cell receptor‐based cancer immunotherapy: Emerging efficacy and pathways of resistance
Chandran, S. S., & Klebanoff, C. A. (2019) · Immunological Reviews · doi:10.1111/imr.12772 · Cited by 325 · see citing works
Ninomiya, S., Narala, N., Huye, L. E., Yagyu, S., Savoldo, B., Dotti, G., Heslop, H. E., Brenner, M. K., Rooney, C. M., & Ramos, C. A. (2015) · Blood · doi:10.1182/blood-2015-01-621474 · Cited by 317 · see citing works
Kershaw, M. H., Wang, G., Westwood, J. A., Pachynski, R. K., Tiffany, H. L., Marincola, F. M., Wang, E., Young, H. A., Murphy, P. M., & Hwu, P. (2002) · Human Gene Therapy · doi:10.1089/10430340260355374 · Cited by 296 · see citing works
Immuno-oncology drug development goes global
Yu, J. X., Hubbard-Lucey, V. M., & Tang, J. (2019) · Nature Reviews Drug Discovery · doi:10.1038/d41573-019-00167-9 · Cited by 262 · see citing works
In Vivo Antitumor Activity of Tumor-Infiltrating Lymphocytes Expanded in Recombinant Interleukin-2
Spiess, P. J., Yang, J. C.-H., & Rosenberg, S. A. (1987) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/79.5.1067 · Cited by 258 · see citing works
Adoptive T Cell Therapies: A Comparison of T Cell Receptors and Chimeric Antigen Receptors
Harris, D. T., & Kranz, D. M. (2015) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2015.11.004 · Cited by 255 · see citing works
Chinnasamy, D., Yu, Z., Theoret, M. R., Zhao, Y., Shrimali, R. K., Morgan, R. A., Feldman, S. A., Restifo, N. P., & Rosenberg, S. A. (2010) · Journal of Clinical Investigation · doi:10.1172/jci43490 · Cited by 253 · see citing works
Zhong, S., Malecek, K., Johnson, L. A., Yu, Z., de Miera, E. V., Darvishian, F., McGary, K., Huang, K. B., Boyer, J., Corse, E., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1221609110 · Cited by 248 · see citing works
Developing neoantigen-targeted T cell–based treatments for solid tumors
Yamamoto, T. N., Kishton, R. J., & Restifo, N. P. (2019) · Nature Medicine · doi:10.1038/s41591-019-0596-y · Cited by 237 · see citing works
Mixed T cell receptor dimers harbor potentially harmful neoreactivity
van Loenen, M. M., de Boer, R., Amir, A. L., Hagedoorn, R. S., Volbeda, G. L., Willemze, R., van Rood, J. J., Falkenburg, J. H. F., & Heemskerk, M. H. M. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1005802107 · Cited by 231 · see citing works
CRISPR-mediated TCR replacement generates superior anticancer transgenic T cells
Legut, M., Dolton, G. M., Mian, A. A., Ottmann, O. G., & Sewell, A. K. (2017) · Blood · doi:10.1182/blood-2017-05-787598 · Cited by 229 · see citing works
Role of memory T cell subsets for adoptive immunotherapy
Busch, D. H., Fräßle, S. P., Sommermeyer, D., Buchholz, V. R., & Riddell, S. R. (2016) · Seminars in Immunology · doi:10.1016/j.smim.2016.02.001 · Cited by 226 · see citing works
Lai, J., Mardiana, S., House, I. G., Sek, K., Henderson, M. A., Giuffrida, L., Chen, A. X. Y., Todd, K. L., Petley, E. V., Chan, J. D., et al. (2020) · Nature Immunology · doi:10.1038/s41590-020-0676-7 · Cited by 222 · see citing works
Best practices for bioinformatic characterization of neoantigens for clinical utility
Richters, M. M., Xia, H., Campbell, K. M., Gillanders, W. E., Griffith, O. L., & Griffith, M. (2019) · Genome Medicine · doi:10.1186/s13073-019-0666-2 · Cited by 212 · see citing works
Yossef, R., Tran, E., Deniger, D. C., Gros, A., Pasetto, A., Parkhurst, M. R., Gartner, J. J., Prickett, T. D., Cafri, G., Robbins, P. F., et al. (2018) · JCI Insight · doi:10.1172/jci.insight.122467 · Cited by 209 · see citing works
Chimeric antigen receptor T cell persistence and memory cell formation
McLellan, A. D., & Rad, S. M. A. H. (2019) · Immunology and Cell Biology · doi:10.1111/imcb.12254 · Cited by 209 · see citing works
T cell exhaustion: from pathophysiological basics to tumor immunotherapy
Catakovic, K., Klieser, E., Neureiter, D., & Geisberger, R. (2017) · Cell Communication and Signaling · doi:10.1186/s12964-016-0160-z · Cited by 202 · see citing works
Gene editing for immune cell therapies
Bailey, S. R., & Maus, M. V. (2019) · Nature Biotechnology · doi:10.1038/s41587-019-0137-8 · Cited by 202 · see citing works
Improving the safety of cell therapy products by suicide gene transfer
Jones, B. S., Lamb, L. S., Goldman, F. D., & Stasi, A. D. (2014) · Frontiers in Pharmacology · doi:10.3389/fphar.2014.00254 · Cited by 201 · see citing works
Adoptive transfer of tumor-infiltrating lymphocytes in melanoma: a viable treatment option
Rohaan, M. W., van den Berg, J. H., Kvistborg, P., & Haanen, J. B. A. G. (2018) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-018-0391-1 · Cited by 196 · see citing works
Prosser, M. E., Brown, C. E., Shami, A. F., Forman, S. J., & Jensen, M. C. (2012) · Molecular Immunology · doi:10.1016/j.molimm.2012.03.023 · Cited by 186 · see citing works
Parkhurst, M. R., Gros, A., Pasetto, A., Prickett, T. D., Crystal, J. S., Robbins, P. F., & Rosenberg, S. A. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-2680 · Cited by 182 · see citing works
Reversal of tumor immune inhibition using a chimeric cytokine receptor.
Leen, A., Sukumaran, S., Watanabe, N., Mohammed, S., Keirnan, J., Yanagisawa, R., Anurathapan, U., Rendon, D. A., Heslop, H., Rooney, C., et al. (2014) · Molecular Therapy · doi:10.1038/mt.2014.47 · Cited by 171 · see citing works
Frequencies of HLA-A2 alleles in five U.S. population groups
Ellis, J. M., Henson, V., Slack, R. S., Ng, J., Hartzman, R. J., & Hurley, C. K. (2000) · Human Immunology · doi:10.1016/s0198-8859(99)00155-x · Cited by 169 · see citing works
Minagawa, A., Yoshikawa, T., Yasukawa, M., Hotta, A., Kunitomo, M., Iriguchi, S., Takiguchi, M., Kassai, Y., Imai, E., Yasui, Y., et al. (2018) · Cell stem cell · doi:10.1016/j.stem.2018.10.005 · Cited by 166 · see citing works
Driving T-cell immunotherapy to solid tumors
Garber, K. (2018) · Nature Biotechnology · doi:10.1038/nbt.4090 · Cited by 155 · see citing works
The Emerging World of TCR-T Cell Trials Against Cancer: A Systematic Review
Zhang, J., & Wang, L. (2019) · Technology in Cancer Research & Treatment · doi:10.1177/1533033819831068 · Cited by 155 · see citing works
Deniger, D. C., Pasetto, A., Robbins, P. F., Gartner, J. J., Prickett, T. D., Paria, B. C., Malekzadeh, P., Jia, L., Yossef, R., Langhan, M. M., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-0573 · Cited by 153 · see citing works
Berdien, B., Mock, U., Atanackovic, D., & Fehse, B. (2014) · Gene Therapy · doi:10.1038/gt.2014.26 · Cited by 148 · see citing works
Zhou, J., Jin, L., Wang, F., Zhang, Y., Liu, B., & Zhao, T. (2019) · Protein & Cell · doi:10.1007/s13238-019-0643-y · Cited by 148 · see citing works
The problem with neoantigen prediction
(2017) · Nature Biotechnology · doi:10.1038/nbt.3800 · Cited by 148 · see citing works
Burris, H. A., Patel, M. R., Cho, D. C., Clarke, J. M., Gutierrez, M., Zaks, T. Z., Frederick, J., Hopson, K., Mody, K., Binanti-Berube, A., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.2019.37.15_suppl.2523 · Cited by 144 · cited 1× · see citing works
“Furthermore, their improved clinical results compared to earlier TAA-directed vaccination efforts, with long-term tumor control in the majority of patients, highlight the superiority of multivalent and TSA-based over single-antigen and TAA-based strategies, and have paved the way for similar vaccination efforts in hea…”
BackgroundDeterminants for Neoantigen Identification
García-Garijo, A., Fajardo, C. A., & Gros, A. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01392 · Cited by 136 · see citing works
CAR T-cell intrinsic PD-1 checkpoint blockade: A two-in-one approach for solid tumor immunotherapy
Chen, N., Morello, A., Tano, Z. E., & Adusumilli, P. S. (2016) · OncoImmunology · doi:10.1080/2162402x.2016.1273302 · Cited by 134 · see citing works
Ochi, T., Fujiwara, H., Okamoto, S., An, J., Nagai, K., Shirakata, T., Mineno, J., Kuzushima, K., Shiku, H., & Yasukawa, M. (2011) · Blood · doi:10.1182/blood-2011-02-337089 · Cited by 121 · see citing works
Endogenous Interleukin-4 Promotes Tumor Development by Increasing Tumor Cell Resistance to Apoptosis
Li, Z., Jiang, J., Wang, Z., Zhang, J., Xiao, M., Wang, C., Yu, L., & Qin, Z. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-0449 · Cited by 114 · see citing works
The promise of γδ T cells and the γδ T cell receptor for cancer immunotherapy
Legut, M., Cole, D. K., & Sewell, A. K. (2015) · Cellular and Molecular Immunology · doi:10.1038/cmi.2015.28 · Cited by 112 · see citing works
van den Berg, J. H., Gomez, R., van de Wiel, B. A., Hulshoff, L., van den Broek, D. A., Bins, A. D., Tan, H. L., Harper, J. V., Hassan, N. J., Jakobsen, B. K., et al. (2015) · Molecular Therapy · doi:10.1038/mt.2015.60 · Cited by 111 · see citing works
Christopoulos, P., Pfeifer, D., Bartholomé, K., Follo, M., Timmer, J., Fisch, P., & Veelken, H. (2011) · Blood · doi:10.1182/blood-2010-07-299321 · Cited by 109 · see citing works
Self-citationInduction of neoantigen-reactive T cells from healthy donors
Ali, M., Földvári, Z., Giannakopoulou, E., Böschen, M.-L., Strønen, E., Yang, W., Toebes, M., Schubert, B., Kohlbacher, O., Schumacher, T. N., et al. (2019) · Nature Protocols · doi:10.1038/s41596-019-0170-6 · Cited by 108 · see citing works
Obenaus, M., Leitão, C., Leisegang, M., Chen, X. T., Gavvovidis, I., van der Bruggen, P., Uckert, W., Schendel, D. J., & Blankenstein, T. J. F. (2015) · Nature Biotechnology · doi:10.1038/nbt.3147 · Cited by 103 · see citing works
Jafarzadeh, L., Masoumi, E., Fallah-Mehrjardi, K., Mirzaei, H. R., & Hadjati, J. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00702 · Cited by 102 · see citing works
Ankri, C., Shamalov, K., Horovitz‐Fried, M., Mauer, S., & Cohen, C. J. (2013) · The Journal of Immunology · doi:10.4049/jimmunol.1203085 · Cited by 101 · see citing works
Vaccines to Prevent Infections by Oncoviruses
Schiller, J. T., & Lowy, D. R. (2010) · Annual Review of Microbiology · doi:10.1146/annurev.micro.112408.134019 · Cited by 101 · see citing works
Peng, P., Cohen, C. J., Yang, S.-C., Hsu, C., Jones, S., Zhao, Y., Zheng, Z.-L., Rosenberg, S. A., & Morgan, R. A. (2009) · Gene Therapy · doi:10.1038/gt.2009.54 · Cited by 100 · see citing works
αβ T-Cell Receptor Engineered γδ T Cells Mediate Effective Antileukemic Reactivity
van der Veken, L. T., Hagedoorn, R. S., van Loenen, M. M., Willemze, R., Falkenburg, J. H. F., & Heemskerk, M. H. M. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-4190 · Cited by 99 · see citing works
Zhang, L., Yu, Z., Muranski, P. J., Palmer, D. C., Restifo, N. P., Rosenberg, S. A., & Morgan, R. (2012) · Gene Therapy · doi:10.1038/gt.2012.75 · Cited by 93 · see citing works
Personalized T cell-mediated cancer immunotherapy: progress and challenges
Bethune, M. T., & Joglekar, A. V. (2017) · Current Opinion in Biotechnology · doi:10.1016/j.copbio.2017.03.024 · Cited by 90 · see citing works
Targeting cancer-specific mutations by T cell receptor gene therapy
Blankenstein, T. J. F., Leisegang, M., Uckert, W., & Schreiber, H. W. (2015) · Current Opinion in Immunology · doi:10.1016/j.coi.2015.02.005 · Cited by 88 · see citing works
Updates on CAR T‐cell therapy in B‐cell malignancies
Jacoby, E., Shahani, S. A., & Shah, N. N. (2019) · Immunological Reviews · doi:10.1111/imr.12774 · Cited by 87 · see citing works
Efficient identification of neoantigen-specific T-cell responses in advanced human ovarian cancer
Liu, S., Matsuzaki, J., Wei, L., Tsuji, T., Battaglia, S., Hu, Q., Cortes, E., Wong, L.-P., Yan, L., Long, M. D., et al. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0629-6 · Cited by 84 · see citing works
Enhancing CAR T-cell therapy through cellular imaging and radiotherapy
Minn, I., Rowe, S. P., & Pomper, M. G. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30461-9 · Cited by 84 · see citing works
Shin, J. H., Park, H. B., Oh, Y. M., Lim, D. P., Lee, J. E., Seo, H. H., Lee, S. J., Eom, H., Kim, I.-H., Lee, S. H., et al. (2012) · Blood · doi:10.1182/blood-2011-09-380519 · Cited by 82 · see citing works
Matsuda, T., Leisegang, M., Park, J.-H., Ren, L., Kato, T., Ikeda, Y., Harada, M., Kiyotani, K., Lengyel, E. R., Fleming, G. F., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-0142 · Cited by 80 · see citing works
Ben-Avi, R., Farhi, R., Ben‐Nun, A., Gorodner, M., Greenberg, E., Markel, G., Schachter, J., Itzhaki, O., & Besser, M. J. (2018) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-018-2174-4 · Cited by 80 · see citing works
NK cells specifically TCR-dressed to kill cancer cells
Mensali, N., Dillard, P., Hebeisen, M., Lorenz, S., Theodossiou, T. A., Myhre, M. R., Fåne, A., Gaudernack, G., Kvalheim, G., Myklebust, J. H., et al. (2019) · EBioMedicine · doi:10.1016/j.ebiom.2019.01.031 · Cited by 80 · see citing works
Menger, L., Śledzińska, A., Bergerhoff, K. F., Vargas, F. A., Smith, J. N. P., Poirot, L., Pulè, M. A., Herrero, J., Peggs, K. S., & Quezada, S. A. (2016) · Cancer Research · doi:10.1158/0008-5472.can-15-3352 · Cited by 79 · see citing works
A TIGIT-based chimeric co-stimulatory switch receptor improves T-cell anti-tumor function
Hoogi, S., Eisenberg, V., Mayer, S., Shamul, A., Barliya, T., & Cohen, C. J. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0721-y · Cited by 79 · see citing works
Dwarshuis, N., Parratt, K. H., Santiago-Miranda, A. N., & Roy, K. (2017) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2017.06.005 · Cited by 78 · see citing works
Idorn, M., Skadborg, S. K., Kellermann, L., Halldórsdóttir, H. R., Olofsson, G. H., Met, Ö., & Straten, P. T. (2018) · OncoImmunology · doi:10.1080/2162402x.2018.1450715 · Cited by 77 · see citing works
Oncolytic Viruses Partner With T-Cell Therapy for Solid Tumor Treatment
Shaw, A. R., & Suzuki, M. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.02103 · Cited by 74 · see citing works
Dual TCR T Cells: Identity Crisis or Multitaskers?
Schuldt, N. J., & Binstadt, B. A. (2019) · The Journal of Immunology · doi:10.4049/jimmunol.1800904 · Cited by 72 · see citing works
Border, E. C., Sanderson, J. P., Weissensteiner, T., Gerry, A. B., & Pumphrey, N. J. (2018) · OncoImmunology · doi:10.1080/2162402x.2018.1532759 · Cited by 70 · see citing works
Rewriting History: Epigenetic Reprogramming of CD8+ T Cell Differentiation to Enhance Immunotherapy
Zebley, C. C., Gottschalk, S. M., & Youngblood, B. (2020) · Trends in Immunology · doi:10.1016/j.it.2020.06.008 · Cited by 70 · see citing works
Seliktar-Ofir, S., Merhavi-Shoham, E., Itzhaki, O., Yunger, S., Markel, G., Schachter, J., & Besser, M. J. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.01211 · Cited by 69 · see citing works
Bunse, M., Bendle, G. M., Linnemann, C., Bies, L., Schulz, S., Schumacher, T. N., & Uckert, W. (2014) · Molecular Therapy · doi:10.1038/mt.2014.142 · Cited by 67 · see citing works
Engineering higher affinity T cell receptors using a T cell display system
Chervin, A. S., Aggen, D. H., Raseman, J. M., & Kranz, D. M. (2008) · Journal of Immunological Methods · doi:10.1016/j.jim.2008.09.016 · Cited by 66 · see citing works
Schmitt, T. M., Aggen, D. H., Stromnes, I. M., Dossett, M. L., Richman, S. A., Kranz, D. M., & Greenberg, P. D. (2013) · Blood · doi:10.1182/blood-2013-01-478164 · Cited by 62 · see citing works
Oda, S. K., Daman, A. W., Garcia, N. M., Wagener, F. D., Schmitt, T. M., Tan, X., Chapuis, A. G., & Greenberg, P. D. (2017) · Blood · doi:10.1182/blood-2017-04-777052 · Cited by 62 · see citing works
Novel Serial Positive Enrichment Technology Enables Clinical Multiparameter Cell Sorting
Stemberger, C., Dreher, S., Tschulik, C., Piossek, C., Bet, J., Yamamoto, T. N., Schiemann, M., Neuenhahn, M., Martin, K., Schlapschy, M., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0035798 · Cited by 60 · see citing works
Galon, J., Rossi, J. M., Turcan, S., Danan, C., Locke, F. L., Neelapu, S. S., Miklos, D. B., Bartlett, N. L., Jacobson, C. A., Braunschweig, I., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.35.15_suppl.3025 · Cited by 56 · see citing works
Evolution of chimeric antigen receptor (CAR) T cell therapy: current status and future perspectives
Lee, Y.-H., & Kim, C. H. (2019) · Archives of Pharmacal Research · doi:10.1007/s12272-019-01136-x · Cited by 48 · see citing works
Kaluza, K. M., Kottke, T. J., Díaz, R. M., Rommelfanger, D. M., Thompson, J., & Vile, R. G. (2012) · Human Gene Therapy · doi:10.1089/hum.2012.030 · Cited by 44 · see citing works
Toward the development of true “off‐the‐shelf” synthetic T‐cell immunotherapy
Iriguchi, S., & Kaneko, S. (2018) · Cancer Science · doi:10.1111/cas.13892 · Cited by 42 · see citing works
Parlar, A., Sayitoğlu, E. C., Özkazanç, D., Georgoudaki, A., Pamukcu, C., Aras, M., Josey, B. J., Chrobok, M., Branecki, S., Zahedimaram, P., et al. (2019) · European Journal of Immunology · doi:10.1002/eji.201948140 · Cited by 42 · see citing works
Martínez-Usatorre, A., Carmona, S. J., Godfroid, C., Maroun, C. Y., Labiano, S., & Romero, P. J. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00340 · Cited by 41 · see citing works
Safety and efficacy of Tet-regulated IL-12 expression in cancer-specific T cells
Alsaieedi, A., Holler, A., Veliça, P., Bendle, G. M., & Stauss, H. J. (2018) · OncoImmunology · doi:10.1080/2162402x.2018.1542917 · Cited by 38 · see citing works
Christopoulos, P., Dopfer, E. P., Malkovský, M., Esser, P. R., Schaefer, H., Marx, A., Kock, S., Rupp, N., Lorenz, M. R., Schwarz, K., et al. (2015) · The Journal of Immunology · doi:10.4049/jimmunol.1402805 · Cited by 37 · see citing works
Self-citationOkamoto, S., Amaishi, Y., Goto, Y., Ikeda, H., Fujiwara, H., Kuzushima, K., Yasukawa, M., Shiku, H., & Mineno, J. (2012) · Molecular Therapy — Nucleic Acids · doi:10.1038/mtna.2012.52 · Cited by 37 · see citing works
Enhanced antitumor activity mediated by human 4‐1BB‐engineered T cells
Daniel‐Meshulam, I., Horovitz‐Fried, M., & Cohen, C. J. (2013) · International Journal of Cancer · doi:10.1002/ijc.28320 · Cited by 34 · see citing works
Biotechnologies to tackle the challenge of neoantigen identification
Arnaud, M., Duchamp, M., Bobisse, S., Renaud, P., Coukos, G., & Harari, A. (2020) · Current Opinion in Biotechnology · doi:10.1016/j.copbio.2019.12.014 · Cited by 33 · see citing works
Gene editing enables T-cell engineering to redirect antigen specificity for potent tumor rejection
Albers, J. J., Ammon, T., Gosmann, D., Audehm, S., Thoene, S., Winter, C., Secci, R., Wolf, A. A., Stelzl, A., Steiger, K., et al. (2019) · Life Science Alliance · doi:10.26508/lsa.201900367 · Cited by 25 · see citing works
The highly alloreactive nature of dual TCR T cells
Balakrishnan, A., & Morris, G. P. (2015) · Current Opinion in Organ Transplantation · doi:10.1097/mot.0000000000000261 · Cited by 24 · see citing works
Acquired T-Cell Immunodeficiency in Thymoma Patients
Christopoulos, P., & Fisch, P. (2016) · Critical Reviews in Immunology · doi:10.1615/critrevimmunol.2017018916 · Cited by 24 · see citing works
Self-citationCombination immunotherapies implementing adoptive T-cell transfer for advanced-stage melanoma
Foley, K. C., Nishimura, M. I., & Moore, T. V. (2018) · Melanoma Research · doi:10.1097/cmr.0000000000000436 · Cited by 24 · see citing works
Immune Modulation in Lung Cancer: Current Concepts and Future Strategies
Gaissmaier, L., & Christopoulos, P. (2020) · Respiration · doi:10.1159/000510385 · Cited by 24 · see citing works
Self-citationPursuit of tumor-infiltrating lymphocyte immunotherapy speeds up
Garber, K. (2019) · Nature Biotechnology · doi:10.1038/d41587-019-00023-6 · Cited by 23 · see citing works
Ghorashian, S., Veliça, P., Chua, I. C., McNicol, A., Carpenter, B., Holler, A., Nicholson, E., Ahmadi, M., Zech, M., Xue, S., et al. (2014) · The Journal of Immunology · doi:10.4049/jimmunol.1401703 · Cited by 22 · see citing works
Orthotopic T-Cell Receptor Replacement—An “Enabler” for TCR-Based Therapies
Schober, K., Müller, T. R., & Busch, D. H. (2020) · Cells · doi:10.3390/cells9061367 · Cited by 22 · see citing works
Miyao, K., Terakura, S., Okuno, S., Julamanee, J., Watanabe, K., Hamana, H., Kishi, H., Sakemura, R. L., Koyama, D., Goto, T., et al. (2018) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-17-0538 · Cited by 20 · see citing works
Christopoulos, P., Schneider, M. A., Bozorgmehr, F., Kuon, J., Engel-Riedel, W., Kollmeier, J., Baum, V., Muley, T., Schnabel, P. A., Bischoff, H. G., et al. (2018) · Lung Cancer · doi:10.1016/j.lungcan.2018.03.002 · Cited by 18 · see citing works
Self-citationReuß, S., Sebestyén, Z., Heinz, N., Loew, R., Baum, C., Debets, R., & Uckert, W. (2013) · European Journal of Immunology · doi:10.1002/eji.201343591 · Cited by 15 · see citing works
Building upon the success of CART19: chimeric antigen receptor T cells for hematologic malignancies
Rotolo, A., Karadimitris, A., & Ruella, M. (2017) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2017.1403024 · Cited by 13 · see citing works
Christopoulos, P., Follo, M., Fisch, P., & Veelken, H. (2008) · Leukemia · doi:10.1038/leu.2008.82 · Cited by 12 · see citing works
Self-citationEngineering CD4+ T Cells to Enhance Cancer Immunity
Sillito, F. E., Holler, A., & Stauss, H. J. (2020) · Cells · doi:10.3390/cells9071721 · Cited by 12 · see citing works
Gene editing: Towards the third generation of adoptive T-cell transfer therapies
Puig-Saus, C., & Ribas, A. (2019) · Immuno-Oncology Technology · doi:10.1016/j.iotech.2019.06.001 · Cited by 11 · see citing works
Christopoulos, P., Chung, I., Bozorgmehr, F., Muley, T., Meister, M. A., Kobinger, S., Marx, A., Thomas, M., Winter, H., Herpel, E., et al. (2018) · Histopathology · doi:10.1111/his.13724 · Cited by 5 · see citing works
Self-citationHLA Loss Facilitates Immune Escape
(2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-nb2017-166 · Cited by 5 · see citing works
Stauss, H. J. (2017) · Oncotarget · doi:10.18632/oncotarget.15088 · Cited by 3 · see citing works
Two Weeks' Notice from Allogeneic Sources
Anczurowski, M., & Hirano, N. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-1552 · Cited by 2 · see citing works
Anderson, V. E., Weber, A. M., Wiedermann, G. E., Pachnio, A., Dauleh, S., Ahmed, T., Docta, R. Y., Quattrini, A., Pope, G., Quinn, L., et al. (2019) · Immunology · doi:10.1158/1538-7445.sabcs18-2313 · Cited by 1 · see citing works
Flagged first, then by citations
1 of the 173 references couldn’t be matched to a known paper.
Research works printed but not linked: 1
- [66]Puig-Saus C. Sennino B. Purandare B. An D. Quach B. Peng S. Xia H. Zhao S. Pan Z. Ma Y. Landscape analysis of neoepitope-specific T-cell responses to immunotherapy The 111th Annual Meeting of the American Association for Cancer Research, Proceedings of the AACR Annual Meeting 2020, Philadelphia, PA, USA, 22–24 June 2020 AACR Philadelphia, PA, USA 2020
Cited by
Sorted by citations
TCR-engineered T cell therapy in solid tumors: State of the art and perspectives
Baulu, E., Gardet, C., Chuvin, N., & Depil, S. (2023) · Science Advances · doi:10.1126/sciadv.adf3700 · Cited by 439 · see citing works
The state of cell and gene therapy in 2023
Chancellor, D., Barrett, D., Nguyen-Jatkoe, L., Millington, S., & Eckhardt, F. (2023) · Molecular Therapy · doi:10.1016/j.ymthe.2023.11.001 · Cited by 149 · see citing works
Principles and Current Clinical Landscape of Multispecific Antibodies against Cancer
Elshiaty, M., Schindler, H., & Christopoulos, P. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22115632 · Cited by 98 · see citing works
Self-citationCancer-associated fibroblasts in colorectal cancer
Zonouzi, S. K., Pezeshki, P. S., Razi, S., & Rezaei, N. (2021) · Clinical & Translational Oncology · doi:10.1007/s12094-021-02734-2 · Cited by 86 · see citing works
Chamberlain, C. A., Bennett, E., Kverneland, A. H., Svane, I. M., Donia, M., & Met, Ö. (2022) · Molecular Therapy — Oncolytics · doi:10.1016/j.omto.2022.01.004 · Cited by 78 · see citing works
Emerging Trends in Immunotherapy for Cancer
Mishra, A., Ali, A., Dutta, S., Banday, S., & Malonia, S. K. (2022) · Diseases · doi:10.3390/diseases10030060 · Cited by 75 · see citing works
Targeting the undruggable oncogenic KRAS: the dawn of hope
Asimgil, H., Ertetik, U., Çevik, N. C., Ekizce, M., Doğruöz, A., Gökalp, M., Sever, E. A., Istvánffy, R., Friess, H., Ceyhan, G. O., et al. (2022) · JCI Insight · doi:10.1172/jci.insight.153688 · Cited by 55 · see citing works
Therapeutic Sequencing in ALK+ NSCLC
Elsayed, M., & Christopoulos, P. (2021) · Pharmaceuticals · doi:10.3390/ph14020080 · Cited by 51 · see citing works
Self-citationUtility and Drawbacks of Chimeric Antigen Receptor T Cell (CAR-T) Therapy in Lung Cancer
Kandra, P., Nandigama, R., Eul, B. G., Huber, M., Kobold, S., Seeger, W., Grimminger, F., & Savai, R. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.903562 · Cited by 48 · see citing works
Current and Future Trends of Colorectal Cancer Treatment: Exploring Advances in Immunotherapy
Nikolouzakis, T. K., Chrysos, E., Docea, A. O., Fragkiadaki, P., Souglakos, J., Tsiaoussis, J., & Tsatsakis, A. (2024) · Cancers · doi:10.3390/cancers16111995 · Cited by 37 · see citing works
T Cell Engaging Immunotherapies, Highlighting Chimeric Antigen Receptor (CAR) T Cell Therapy
Bousser, E. D., Callewaert, N., & Festjens, N. (2021) · Cancers · doi:10.3390/cancers13236067 · Cited by 38 · see citing works
Immune Modulation in Lung Cancer: Current Concepts and Future Strategies
Gaissmaier, L., & Christopoulos, P. (2020) · Respiration · doi:10.1159/000510385 · Cited by 24 · see citing works
Self-citationTCR gene-engineered cell therapy for solid tumors
Tan, E. S., Gakhar, N., & Kirtane, K. (2021) · Best Practice & Research Clinical Haematology · doi:10.1016/j.beha.2021.101285 · Cited by 23 · see citing works
Leveraging biomaterials for enhancing T cell immunotherapy
Liao, Z., Zhang, W., Zheng, H., Wang, Y., Yu, J., Li, H., & Gu, Z. (2022) · Journal of Controlled Release · doi:10.1016/j.jconrel.2022.02.023 · Cited by 22 · see citing works
Li, X., Jian, J., Zhang, A., Xiang, J., Huang, J., & Chen, Y. (2024) · Scientific Reports · doi:10.1038/s41598-024-69187-9 · Cited by 20 · see citing works
Current State of Cell Therapies for Breast Cancer
Gautam, N., Elleson, K. M., Ramamoorthi, G., & Czerniecki, B. J. (2022) · The Cancer Journal · doi:10.1097/ppo.0000000000000607 · Cited by 19 · see citing works
Blasi, M., Kuon, J., Shah, R., Bozorgmehr, F., Eichhorn, F., Liersch, S., Stenzinger, A., Heußel, C. P., Herth, F. J. F., Thomas, M., et al. (2023) · Clinical Lung Cancer · doi:10.1016/j.cllc.2023.06.010 · Cited by 17 · see citing works
Self-citationYu, J., Wang, Q., Zhang, X., Guo, Z., & Cui, X. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.685377 · Cited by 16 · see citing works
Huynh, D., Winter, P., Märkl, F., Endres, S., & Kobold, S. (2022) · Seminars in Immunopathology · doi:10.1007/s00281-022-00962-4 · Cited by 15 · see citing works
Advances in adoptive cellular therapy for colorectal cancer: A narrative review
Yi, X., & Hu, W. (2022) · Annals of Translational Medicine · doi:10.21037/atm-22-6196 · Cited by 14 · see citing works
Acharya, U. H., & Walter, R. B. (2020) · Cancers · doi:10.3390/cancers12123617 · Cited by 13 · see citing works
The Promise of Personalized TCR-Based Cellular Immunotherapy for Cancer Patients
Arnaud, M., Bobisse, S., Chiffelle, J., & Harari, A. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.701636 · Cited by 12 · see citing works
Adoptive cell therapies in thoracic malignancies
Lasvergnas, J., Naigeon, M., Chouahnia, K., Zelek, L. H., Chaput, N., & Duchemann, B. (2022) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-022-03142-3 · Cited by 12 · see citing works
Drug Repurposing by Tumor Tissue Editing
Lüke, F., Harrer, D. C., Pantziarka, P., Pukrop, T., Ghibelli, L., Gerner, C., Reichle, A., & Heudobler, D. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.900985 · Cited by 11 · see citing works
Tieng, F. Y. F., Lee, L., & Mutalib, N. A. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.959705 · Cited by 10 · see citing works
Central IRF4/5 Signaling Are Critical for Microglial Activation and Impact on Stroke Outcomes
Ngwa, C., Mamun, A. A., Qi, S., Sharmeen, R., Conesa, M. P. B., Ganesh, B. P., Manwani, B., & Liu, F. (2023) · Translational Stroke Research · doi:10.1007/s12975-023-01172-2 · Cited by 11 · see citing works
Kroonen, J. S., Wouters, A. K., de Graaf, I. J., Remst, D. F. G., Kumar, S., Wachsmann, T. L. A., Teunisse, A. F. A. S., Roelands, J. P., de Miranda, N. F. C. C., Griffioen, M., et al. (2024) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2023-008654 · Cited by 9 · see citing works
Anaplastic lymphoma kinase-special immunity and immunotherapy
Guo, Y., Guo, H., Zhang, Y., & Cui, J. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.908894 · Cited by 9 · see citing works
Addressing the unmet need in NSCLC progression with advances in second-line therapeutics
Wang, K., Leyba, A., & Hsu, R. C. (2024) · Exploration of Targeted Anti-tumor Therapy · doi:10.37349/etat.2024.00277 · Cited by 8 · see citing works
Adoptive immune cell therapy for colorectal cancer
Liu, C., Liu, N., Zhang, T., & Tu, Y. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1557906 · Cited by 8 · see citing works
TCR Gene Therapy: Challenges, Opportunities, and Future Directions
Stauss, H. J., & Tran, M. G. B. (2020) · Cells · doi:10.3390/cells9122567 · Cited by 8 · see citing works
Role of Metabolism in Adoptive T Cell Therapy: Strategies and Challenges
Tan, G. H., & Wong, C. C. (2022) · Antioxidants and Redox Signaling · doi:10.1089/ars.2022.0037 · Cited by 6 · see citing works
Dimitrakopoulou‐Strauss, A., Sachpekidis, C., Hassel, J. C., & Christopoulos, P. (2023) · Cancer Biotherapy and Radiopharmaceuticals · doi:10.1089/cbr.2022.0067 · Cited by 5 · see citing works
Self-citationGrigoruţă, M., Kong, X., & Qin, Y. W. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14145137 · Cited by 4 · see citing works
Design of TCR Structural Variants That Retain or Invert the Normal Activation Signal
Mock, J., Oh, J., Yi, J., Daris, M. E., Hamburger, A. E., & Kamb, A. (2021) · ImmunoHorizons · doi:10.4049/immunohorizons.2100033 · Cited by 4 · see citing works
Tackling the challenge of brain involvement in driver-negative non-small cell lung cancer
Christopoulos, P. (2023) · Translational Lung Cancer Research · doi:10.21037/tlcr-23-347 · Cited by 3 · see citing works
Self-citationFestag, J., Festag, M. M., Asen, T., Wettengel, J. M., Mück-Häusl, M., Abdulhaqq, S. A., Stahl‐Hennig, C., Sacha, J. B., Burwitz, B. J., Protzer, U., et al. (2023) · Human Gene Therapy · doi:10.1089/hum.2023.035 · Cited by 3 · see citing works
Nanomedicine in Immunotherapy for Non‐Small Cell Lung Cancer: Applications and Perspectives
Liao, S., Li, X., Lü, Y., & Luo, K. (2025) · Small Methods · doi:10.1002/smtd.202401783 · Cited by 3 · see citing works
Understanding TCR T cell knockout behavior using interpretable machine learning
Blennemann, M., Verma, A., Bachl, S., Carnevale, J. C., & Engelhardt, B. E. (2024) · Pacific Symposium on Biocomputing (PSB) · doi:10.1142/9789819807024_0028 · Cited by 1 · see citing works
Jiang, M. H., Sun, W., Lu, D., He, J., Wang, J., Tan, S., & Gao, G. F. (2022) · Chinese Science Bulletin (Chinese Version) · doi:10.1360/tb-2022-0235 · Cited by 2 · see citing works
Double trouble: combined large-cell neuroendocrine and small-cell lung carcinoma
Fisch, D., & Christopoulos, P. (2022) · Translational Cancer Research · doi:10.21037/tcr-22-1984 · Cited by 2 · see citing works
Self-citationCan we cure metastatic EGFR-mutated lung cancer today?
Christopoulos, P. (2023) · Translational Cancer Research · doi:10.21037/tcr-22-2926 · Cited by 2 · see citing works
Self-citationTargeted Ablation of Canonical Disulfide Bonds Mitigates TCR Mismatching in Engineered T CellsPreprint
Su, D., & Liu, G. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.05.28.656745 · Cited by 2 · see citing works
Jiménez-Chávez, Á. D. J., & Moreno‐Fierros, L. (2022) · Nano LIFE · doi:10.1142/s1793984422300047 · Cited by 1 · see citing works
Approches d’immunothérapie cellulaire T dans les tumeurs solides
Baulu, E., Dougé, A., Chuvin, N., Bay, J., & Depil, S. (2021) · Bulletin du Cancer · doi:10.1016/j.bulcan.2021.06.004 · Cited by 1 · see citing works
Christopoulos, P., & Gaipl, U. S. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1182081 · Cited by 1 · see citing works
Self-citationChristopoulos, P. (2023) · Deutsches Ärzteblatt · doi:10.3238/personko.2023.03.03.02
Self-citationUnravelling the puzzle of immunotherapeutic efficacy in lung cancer
Christopoulos, P. (2024) · Translational Lung Cancer Research · doi:10.21037/tlcr-24-221
Self-citationAdvancements and Challenges in Cancer Immunotherapy
Dey, P., Bhattacharjee, M., Ghosh, M., & Giri, S. (2024) · Advances in medical diagnosis, treatment, and care (AMDTC) book series · doi:10.4018/979-8-3693-3976-3.ch001
Malleswari, K., Reddy, D. R. B., Rani, B. S. R. B. S., Manmitha, B. S., & Bellala, V. M. (2025) · International Journal of Pharmaceutical Research and Applications · doi:10.35629/4494-100320832091
Neoantigen-based TCR-T therapy in solid tumors
Feng, W., Wu, D., & Li, Y. (2025) · International review of cytology · doi:10.1016/bs.ircmb.2025.11.001
Current Management and the New Paradigm for ALK+ NSCLC After CROWN
Shi, S., & Christopoulos, P. (2026) · Cancers · doi:10.3390/cancers18183044
Self-citation
- Authors
- Gaissmaier, L., Elshiaty, M., & Christopoulos, P.
- Affiliations
- University Hospital Heidelberg (DE)
- Corresponding author
- Christopoulos, Petros
- Venue
- Cells
- Publisher
- MDPI AG
- Published
- 2020-09-14
- Volume
- 9
- Issue
- 9
- Pages
- 2095
- ISSN
- 2073-4409 (ISSN-L)
- PMC
- PMC7564186
- OpenAlex
- W3084571996
- Cited by
- 52
- References
- 173
- Citations by year
- 2026: 1 · 2025: 6 · 2024: 7 · 2023: 10 · 2022: 16 · 2021: 9 · 2020: 3
- FWCI
- 1.02
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Cells (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Deutsche Zentrum für Lungenforschung (DZL 2.0)
- Topics
- Health Sciences › Medicine › Oncology › CAR-T cell therapy research
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Keywords
- T cell receptor gene therapy, cancer immunotherapy, neoantigens, tumor-specific T cells, next-generation sequencing, allogeneic T cells, autologous T cells, T cell exhaustion, tumor microenvironment, memory T cells, solid tumors
- MeSH terms
- Receptors, Chimeric Antigen, Animals, Antigens, Neoplasm, Humans, Neoplasms, Immunotherapy, Adoptive, Tumor Microenvironment, Cell Engineering
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
